Genomictree Inc. (KOSDAQ:228760)

South Korea flag South Korea · Delayed Price · Currency is KRW
11,430
+1,150 (11.19%)
Jun 29, 2026, 3:30 PM KST
Market Cap280.03B -12.2%
Revenue (ttm)3.83B +59.8%
Net Income-8.02B
EPS-333.36
Shares Out 24.50M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume84,761
Open10,280
Previous Close10,280
Day's Range10,280 - 11,470
52-Week Range10,010 - 33,300
Beta0.05
Analystsn/a
Price Targetn/a
Earnings DateAug 14, 2026

About Genomictree

Genomictree Inc., a biomarker-based molecular diagnostics company, develops and commercializes molecular diagnostic products for the detection of cancer and various infectious diseases. The company offers EarlyTect C, a screening method for early diagnosis of colorectal cancer; EarlyTect L for detection of epigenetic markers associated with lung cancer in pulmonary nodule patients; and EarlyTect B for detection of genetic and epigenetic markers associated with bladder cancer in hematuria patients. It also provides AccuraDTect SARS-CoV-2 RT-qPCR... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 228760
Full Company Profile

Financial Performance

In 2025, Genomictree's revenue was 3.76 billion, an increase of 59.17% compared to the previous year's 2.36 billion. Losses were -8.99 billion, -12.27% less than in 2024.

Financial Statements